ARTL (Artelo Biosciences) Cash per Share : $0.71 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Artelo Biosciences Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Artelo Biosciences's Cash per Share for the quarter that ended in Dec. 2024 was $0.71.

Artelo Biosciences Cash per Share Historical Data

The historical data trend for Artelo Biosciences's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Cash per Share Chart

Artelo Biosciences Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Dec24

Cash per Share

Get a 7-Day Free Trial

6.43

6.16

6.14

3.27

0.71

Artelo Biosciences Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash per Share	Get a 7-Day Free Trial															3.27	2.36	1.74	1.51	0.71

Artelo Biosciences Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Artelo Biosciences's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	2.338	/	3.28
	=	0.71

Artelo Biosciences's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	2.338	/	3.28
	=	0.71

Artelo Biosciences (NAS:ARTL) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Artelo Biosciences Cash per Share Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTL) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Executives

Gregory D. Gorgas	director, officer: See Remarks	888 PROSPECT, SUITE 210, LA JOLLA CA 92037
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Gregory Reyes	director	200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121
John W Beck	director	C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Robert Martin Emanuele	director
David J Moss	10 percent owner	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Georgia Erbez	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Steven Kelly	director	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Douglas Blayney	director	C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037
Peter Michael O'brien	10 percent owner	C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037